Clinical outcomes in COVID-19 patients treated with baricitinib
| All cases | <65 years old | >65 years old | |
| Population | |||
| Number of patents | 202 | 146 | 56 |
| Female, % | 48 | 47 | 52 |
| Mean age (range), years | 58 (25–92) | 52 (25–64) | 75 (65–92) |
| Mean treatment duration (range), days | 6 (1–35) | 6 (1–11) | 7 (1–35) |
| Dexamethasone, % | 7.4 | 7.5 | 7.1 |
| Disease (on admission) | |||
| Clinical severity, % | |||
| Mild | 3.0 | 3.4 | 1.8 |
| Moderate | 95.0 | 95.2 | 94.6 |
| Severe | 2.0 | 1.4 | 3.6 |
| Critical | 0 | 1.0 | 0 |
| Lung involvement, % | |||
| CT 0 | 0 | 0 | 0 |
| CT 1 | 8.0 | 7.5 | 19.0 |
| CT 2 | 71.2 | 68.5 | 78.5 |
| CT 3 | 20.8 | 24.0 | 12.5 |
| CT 4 | 0 | 0 | 0 |
| C reactive protein: clinically significant abnormality, % | 95 | 92 | 100 |
| Outcomes | |||
| Death, n (%) | 9 (4.5) | 3 (2.1) | 6 (10.7) |
| Mean from hospitalisation till death (range), days | 12 (2–32) | 14 (2–32) | 12 (5–20) |
| ICU admission, n (%) | 19 (9.4) | 10 (6.9) | 9 (16.1) |
| Mean stay in ICU (range), days | 7 (1–30) | 9 (1–30) | 5 (1–13) |
| Mechanical ventilation, n (%) | 8 (4.0) | 4 (2.8) | 4 (7.1) |
| Mean duration of mechanical vent. (range), days | 7 (2–22) | 9 (3–22) | 6 (2–13) |
| Safety | |||
| Thromboses, n (%) | 1 (0.5) | 0 (0) | 1 (1.8) |
| Pulmonary embolism, n (%) | 1 (0.5) | 0 (0) | 1 (1.8) |
| Infectious complications, n (%) | 7 (3.5) | 4 (2.8) | 3 (5.4) |
ICU, intensive care unit.